An antibody's class and the design of its stem change how it connects to immune cells and complement. Switching off one connection does not switch off all of them, and does not make the finished drug harmless.
An isotype is a heavy-chain class: IgM, IgD, IgG, IgA or IgE, and human IgG also has the subclasses IgG1, IgG2, IgG3 and IgG4. The classes differ in architecture, distribution and potential effector interactions. Vidarsson et al. (2014) review how the four IgG subclasses differ in their hinges and upper CH2 domains, which bind Fc gamma receptors and C1q, giving different effector functions, while the Fc also carries a binding site for the neonatal Fc receptor (FcRn) that extends half-life. A B-cell lineage can undergo class switching, changing the constant region while keeping the rearranged variable-region sequence; this differs from the mutations that change affinity during a response, and neither the class nor a switch says what antigen an antibody recognises. Subclass, Fc sugars, target geometry and the available cells all affect interactions, so IgG1 and IgG4 are not interchangeable but neither name fully predicts behaviour. As a real example, pembrolizumab is a humanised IgG4 kappa antibody (FDA label, section 11); its intended job is to block the PD-1 receptor, not to recruit killer cells to the T cells it binds.
Fc silencing uses design changes to reduce selected receptor or complement interactions. Lo et al. (2017) found that the commonly used N297G and D265A/N297G variants, effective at attenuating effector function in primates, retained potent complement activation in mice and created safety liabilities in murine studies, whereas an L234A, L235A, P329G (LALA-PG) variant eliminated complement binding and attenuated effector activity in that setting. That supports engineering a particular interaction in a particular species; it does not prove universal human safety or silence in every assay. IgG4 is not a synonym for a fully silent Fc.
FcRn has a separate role in IgG transport and recycling, so reduced Fc gamma receptor recruitment does not by itself establish reduced FcRn binding or a shorter half-life. Compare matched molecules with the same binding regions and measure target binding, Fc gamma receptor and C1q binding, and killing, engulfment or complement damage separately, stating species, receptor variants, concentrations and effector cells; FcRn binding and exposure are further questions. An antibody meant to remove a target-bearing cell may benefit from effector recruitment, whereas one meant to block an immune receptor may need to avoid removing useful receptor-bearing cells, but Fc attenuation alone does not establish loss of target binding or absence of payload toxicity or inflammation.
In plain words · FCGR3A encodes CD16A, an IgG Fc receptor involved in NK-cell responses to antibody-coated targets. Binding alone does not establish completed killing.
Showing the target this term concerns: FCGR3A.
Shares Antibody and the tag education-immunology-2026-11.
Shares FCGR3A, Antibody-guided effector mechanisms (ADCC, ADCP, CDC), Fc engineering / effector function, Antibody.
Shares FCGR3A, Antibody-guided effector mechanisms (ADCC, ADCP, CDC), Fc engineering / effector function.
Shares Antibody-guided effector mechanisms (ADCC, ADCP, CDC), Antibody.
Shares FCGR3A, Fc engineering / effector function.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/